Samuel C. Mok, Ph.D.
Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery
About Dr. Mok
Our primary research focus is on studying the role of tumor microenvironment in the pathogenesis of epithelial ovarian cancer. We are particularly interested in evaluating the mechanisms by which stromal cells and ovarian cancer cells interact in the omental tumor microenvironment. Ongoing research projects include the use of next generation RNAseq to characterize non-coding RNAs and mRNAs in immune cells, cancer associated adipocyte (CAA), cancer associated fibroblast (CAF) and ovarian cancer cell- and stromal cell-derived exosomes and microvesicles; the use of transcriptomic profiling, microdissection techniques, and systems biology approach to identify pathway networks that are activated in different cell types within the ovarian cancer microenvironment; and the study of the impact of rigidity of the extracellular matrix on ovarian cancer cell motility, invasion potential, and chemoresistance. Additionally, our laboratory has an interest in identifying diagnostic, prognostic and predictive markers for ovarian cancer through transcriptomic, lipidomic and metabolomic profiling. We are specifically interested in functionally characterizing candidates that may be used as therapeutic targets in ovarian cancer treatment and as diagnostic biomarkers for early detection of the disease.
Present Title & Affiliation
Primary Appointment
Professor, Department of Gynecologic Oncology and Reproductive Medicine - Research, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
My laboratory has a primary research focus on the use of molecular biological techniques to investigate the role of the tumor microenvironment in the pathogenesis of ovarian cancer and endometrial cancer, and identify biomarkers for early detection of ovarian cancer. My laboratory’s ongoing research projects involve the use of oligonucleotide microarrays and RNAseq to identify differentially expressed mRNAs, non-coding RNAs, and DNA copy number abnormalities in microdissected stromal and epithelial components of primary and recurrent high-grade serous ovarian and endometrial tumor tissue samples. In addition, my laboratory has also been developing spatially resolved multi-omics pipelines including using spatial transcriptomics (ST), mass spectrometry imaging (MSI), imaging mass cytometry (IMC), amd multiplex immunofluorescence platforms to identify spatially resolved metabolomic, lipidomics, cellular and molecular profiles in ovarian and endometrial cancer tissue samples. We have been focusing on the identification of altered stromal-epithelial crosstalk networks among various cell types in the tumor microenvironment, and functional studies of genes that may be used as therapeutic targets in ovarian cancer treatment and as diagnostic biomarkers for early detection of the disease.
Education & Training
Degree-Granting Education
| 1987 | The Chinese University of Hong Kong, Hong Kong, HKG, PHD, Anatomy |
| 1984 | The Chinese University of Hong Kong, Hong Kong, HKG, BS, Biology |
Postgraduate Training
| 1990-1992 | Postdoctoral Fellow, Gynecologic Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA |
| 1989-1990 | Postdoctoral Fellow, Department of Immunology, Toronto Western Hospital, Toronto |
| 1987-1989 | Postdoctoral Fellow, Department of Clinical Biochemistry, University of Toronto, Toronto |
Experience & Service
Academic Appointments
Associate Professor, Department of Obstetrics, Division of Gynecology and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 1998 - 2008
Administrative Appointments/Responsibilities
Chief, Department of Gynecologic Oncology and Reproductive Medicine - Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - Present
Selected Publications
Peer-Reviewed Articles
- Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AK. Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight 6(7), 2021. e-Pub 2021. PMID: 33793425.
- Hu W, Zhang L, Ferri-Borgogno S, Kwan SY, Lewis KE, Cun HT, Yeung TL, Soliman PT, Tarapore RS, Allen JE, Guan X, Lu KH, Mok SC, Au-Yeung CL. Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype. Cancers (Basel) 12(9), 2020. e-Pub 2020. PMID: 32867127.
- Au-Yeung CL, Yeung TL, Achreja A, Zhao H, Yip KP, Kwan SY, Onstad M, Sheng J, Zhu Y, Baluya DL, Co NN, Rynne-Vidal A, Schmandt R, Anderson ML, Lu KH, Wong STC, Nagrath D, Mok SC. ITLN1 modulates invasive potential and metabolic reprogramming of ovarian cancer cells in omental microenvironment. Nat Commun 11(1):3546, 2020. e-Pub 2020. PMID: 32669559.
- Colvin EK, Howell VM, Mok SC, Samimi G, Vafaee F. Expression of lncRNAs in cancer-associated fibroblasts linked to patient survival in ovarian cancer. Cancer Sci 111(5):1805-1817, 2020. e-Pub 2020. PMID: 32058624.
- Yeung TL, Sheng J, Leung CS, Li F, Kim J, Ho SY, Matzuk MM, Lu KH, Wong STC, Mok SC. Systematic Identification of Druggable Epithelial-Stromal Crosstalk Signaling Networks in Ovarian Cancer. J Natl Cancer Inst. e-Pub 2018. PMID: 29860390.
- Leung CS, Yeung TL, Yip KP, Wong KK, Ho SY, Mangala LS, Sood AK, Lopez-Berestein G, Sheng J, Wong ST, Birrer MJ, Mok SC. Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance. J Clin Invest 128(2):589-606, 2018. e-Pub 2017. PMID: 29251630.
- Lewis KE, Lu KH, Klimczak AM, Mok SC. Recommendations and Choices for BRCA Mutation Carriers at Risk for Ovarian Cancer: A Complicated Decision. Cancers (Basel) 10(2), 2018. e-Pub 2018. PMID: 29466291.
- Vafaee F, Colvin EK, Mok SC, Howell VM, Samimi G. Functional prediction of long non-coding RNAs in ovarian cancer-associated fibroblasts indicate a potential role in metastasis. Sci Rep 7(1):10374, 2017. e-Pub 2017. PMID: 28871211.
- Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AK. Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight 2(16). e-Pub 2017. PMID: 28814667.
- Rynne-Vidal A, Au-Yeung CL, Jiménez-Heffernan JA, Pérez-Lozano ML, Cremades-Jimeno L, Bárcena C, Cristóbal-García I, Fernández-Chacón C, Yeung TL, Mok SC, Sandoval P, López-Cabrera M. Mesothelial-to-mesenchymal transition as a possible therapeutic target in peritoneal metastasis of ovarian cancer. J Pathol 242(2):140-151, 2017. e-Pub 2017. PMID: 28247413.
- Yeung TL, Leung CS, Wong KK, Gutierrez-Hartmann A, Kwong J, Gershenson DM, Mok SC. ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells. Oncotarget 8(10):16951-16963, 2017. e-Pub 2017. PMID: 28199976.
- Pakish JB, Zhang Q, Chen Z, Liang H, Chisholm G, Yuan Y, Mok SC, Broaddus RJ, Lu K, Yates MS. Immune microenvironment in microsatellite instable endometrial cancers: Hereditary or sporadic origin matters. Clin Cancer Res. e-Pub 2017. PMID: 28264871.
- Lo CM, Lo JC, Sato PY, Yeung TL, Mok SC, Yip KP. Monitoring of ovarian cancer cell invasion in real time with frequency-dependent impedance measurement. Am J Physiol Cell Physiol 311(6):ajpcell.00211.2016, 2016. e-Pub 2016. PMID: 27784677.
- Yang L, Achreja A, Yeung TL, Mangala LS, Jiang D, Han C, Baddour J, Marini JC, Ni J, Nakahara R, Wahlig S, Chiba L, Kim SH, Morse J, Pradeep S, Nagaraja AS, Haemmerle M, Kyunghee N, Derichsweiler M, Plackemeier T, Mercado-Uribe I, Lopez-Berestein G, Moss T, Ram PT, Liu J, Lu X, Mok SC, Sood AK, Nagrath D. Targeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell Growth. Cell Metab 24(5):685-700, 2016. PMID: 27829138.
- Au Yeung CL, Co NN, Tsuruga T, Yeung TL, Kwan SY, Leung CS, Li Y, Lu ES, Kwan K, Wong KK, Schmandt R, Lu KH, Mok SC. Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nat Commun 7:11150, 2016. e-Pub 2016. PMID: 27021436.
- Guo F, Wang Y, Liu J, Mok SC, Xue F, Zhang W. CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks. Oncogene 35(7):816-26, 2016. e-Pub 2015. PMID: 25961926.
- Yeung TL, Leung CS, Li F, Wong SS, Mok SC. Targeting Stromal-Cancer Cell Crosstalk Networks in Ovarian Cancer Treatment. Biomolecules 6(1):3, 2016. e-Pub 2016. PMID: 26751490.
- Moran-Jones K, Gloss BS, Murali R, Chang DK, Colvin EK, Jones MD, Yuen S, Howell VM, Brown LM, Wong CW, Spong SM, Scarlett CJ, Hacker NF, Ghosh S, Mok SC, Birrer MJ, Samimi G. Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer. Oncotarget 6(42):44551-62, 2015. e-Pub 2015. PMID: 26575166.
- Qiu MT, Fan Q, Zhu Z, Kwan SY, Chen L, Chen JH, Ying ZL, Zhou Y, Gu W, Wang LH, Cheng WW, Zeng J, Wan XP, Mok SC, Wong KK, Bao W. KDM4B and KDM4A promote endometrial cancer progression by regulating androgen receptor, c-myc, and p27kip1. Oncotarget 6(31):31702-20, 2015. PMID: 26397136.
- Mok S, Tsoi J, Koya RC, Hu-Lieskovan S, West BL, Bollag G, Graeber TG, Ribas A. Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition. BMC Cancer 15:356, 2015. e-Pub 2015. PMID: 25939769.
- Co NN, Iglesias D, Celestino J, Kwan SY, Mok SC, Schmandt R, Lu KH. Loss of LKB1 in high-grade endometrial carcinoma: LKB1 is a novel transcriptional target of p53. Cancer 120(22):3457-68, 2014. e-Pub 2014. PMID: 25042259.
- Leung CS, Yeung TL, Yip KP, Pradeep S, Balasubramanian L, Liu J, Wong KK, Mangala LS, Armaiz-Pena GN, Lopez-Berestein G, Sood AK, Birrer MJ, Mok SC. Calcium-dependent FAK/CREB/TNNC1 signaling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential. Nat Commun 5:5092, 2014. e-Pub 2014. PMID: 25277212.
- Yeung TL, Leung CS, Mok SC. CAF reprogramming inhibits ovarian cancer progression. Cell Cycle 13(24):0, 2014. e-Pub 2014. PMID: 25483059.
- Tsang YT, Deavers MT, Sun CC, Kwan SY, Kuo E, Malpica A, Mok SC, Gershenson DM, Wong KK. KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma. J Pathol 231(4):449-56, 2013. PMID: 24549645.
- Wei W, Mok SC, Oliva E, Kim SH, Mohapatra G, Birrer MJ. FGF18 as a prognostic and therapeutic biomarker in ovarian cancer. J Clin Invest 123(10):4435-48, 2013. e-Pub 2013. PMID: 24018557.
- Wong KK, Izaguirre DI, Kwan SY, King ER, Deavers MT, Sood AK, Mok SC, Gershenson DM. Poor survival with wild-type TP53 ovarian cancer?. Gynecol Oncol 130(3):565-9, 2013. e-Pub 2013. PMID: 23800698.
- Yeung TL, Leung CS, Wong KK, Samimi G, Thompson MS, Liu J, Zaid TM, Ghosh S, Birrer MJ, Mok SC. TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. Cancer Res 73(16):5016-5028, 2013. e-Pub 2013. PMID: 23824740.
- Zaid TM, Yeung TL, Thompson MS, Leung CS, Harding T, Co NN, Schmandt RS, Kwan SY, Rodriguez-Aguay C, Lopez-Berestein G, Sood AK, Wong KK, Birrer MJ, Mok SC. Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer. Clin Cancer Res 19(4):809-20, 2013. e-Pub 2013. PMID: 23344261.
- Song H, Kwan SY, Izaguirre DI, Zu Z, Tsang YT, Tung CS, King ER, Mok SC, Gershenson DM, Wong KK. PAX2 Expression in Ovarian Cancer. Int J Mol Sci 14(3):6090-105, 2013. e-Pub 2013. PMID: 23502471.
- Merritt MA, Bentink S, Schwede M, Iwanicki MP, Quackenbush J, Woo T, Agoston ES, Reinhardt F, Crum CP, Berkowitz RS, Mok SC, Witt AE, Jones MA, Wang B, Ince TA. Gene Expression Signature of Normal Cell-of-Origin Predicts Ovarian Tumor Outcomes. PLoS One 8(11):e80314, 2013. e-Pub 2013. PMID: 24303006.
- Nowicka A, Marini FC, Solley TN, Elizondo PB, Zhang Y, Sharp HJ, Broaddus R, Kolonin M, Mok SC, Thompson MS, Woodward WA, Lu K, Salimian B, Nagrath D, Klopp AH. Human omental-derived adipose stem cells increase ovarian cancer proliferation, migration, and chemoresistance. PLoS One 8(12):e81859, 2013. e-Pub 2013. PMID: 24312594.
- Chung TK, Lau TS, Cheung TH, Yim SF, Lo KW, Siu NS, Chan LK, Yu MY, Kwong J, Doran G, Barroilhet LM, Ng AS, Wong RR, Wang VW, Mok SC, Smith DI, Berkowitz RS, Wong YF. Dysregulation of microRNA-204 mediates migration and invasion of endometrial cancer by regulating FOXC1. Int J Cancer 130(5):1036-45, 2012. e-Pub 2011. PMID: 21400511.
- Vathipadiekal V, Saxena D, Mok SC, Hauschka PV, Ozbun L, Birrer MJ. Identification of a potential ovarian cancer stem cell gene expression profile from advanced stage papillary serous ovarian cancer. PLoS One 7(1):e29079, 2012. e-Pub 2012. PMID: 22272227.
- King ER, Zu Z, Tsang YT, Deavers MT, Malpica A, Mok SC, Gershenson DM, Wong KK. The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma. Gynecol Oncol 123(1):13-8, 2011. e-Pub 2011. PMID: 21726895.
- King ER, Tung CS, Tsang YT, Zu Z, Lok GT, Deavers MT, Malpica A, Wolf JK, Lu KH, Birrer MJ, Mok SC, Gershenson DM, Wong KK. The Anterior Gradient Homolog 3 (AGR3) Gene Is Associated With Differentiation and Survival in Ovarian Cancer. Am J Surg Pathol 35(6):904-12, 2011. e-Pub 2011. PMID: 21451362.
- Schauer IG, Sood AK, Mok S, Liu J. Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer. Neoplasia 13(5):393-405, 2011. PMID: 21532880.
- Gao Z, Xu X, McClane B, Zeng Q, Litkouhi B, Welch WR, Berkowitz RS, Mok SC, Garner EI. C-Terminus of Clostridium perfringens Enterotoxin Downregulates CLDN4 and Sensitizes Ovarian Cancer Cells to Taxol and Carboplatin. Clin Cancer Res 17(5):1065-74, 2011. e-Pub 2010. PMID: 21123456.
- Yates MS, Meyer LA, Deavers MT, Daniels MS, Keeler ER, Mok SC, Gershenson DM, Lu KH. Microscopic and early stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesis. Cancer Prev Res (Phila) 4(3):463-70, 2011. e-Pub 2011. PMID: 21278312.
- Young JL, Koon EC, Kwong J, Welch WR, Muto MG, Berkowitz RS, Mok SC. Differential hRad17 expression by histologic subtype of ovarian cancer. J Ovarian Res 4(1):6, 2011. e-Pub 2011. PMID: 21450056.
- Stany MP, Vathipadiekal V, Ozbun L, Stone RL, Mok SC, Xue H, Kagami T, Wang Y, McAlpine JN, Bowtell D, Gout PW, Miller DM, Gilks CB, Huntsman DG, Ellard SL, Wang YZ, Vivas-Mejia P, Lopez-Berestein G, Sood AK, Birrer MJ. Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. PLoS One 6(7):e21121, 2011. e-Pub 2011. PMID: 21754983.
- Ghosh S, Albitar L, LeBaron R, Welch WR, Samimi G, Birrer MJ, Berkowitz RS, Mok SC. Up-regulation of stromal versican expression in advanced stage serous ovarian cancer. Gynecol Oncol 119(1):114-20, 2010. e-Pub 2010. PMID: 20619446.
- Wong KK, Tsang YT, Deavers MT, Mok SC, Zu Z, Sun C, Malpica A, Wolf JK, Lu KH, Gershenson DM. BRAF Mutation Is Rare in Advanced-Stage Low-Grade Ovarian Serous Carcinomas. Am J Pathol 177(4):1611-7, 2010. e-Pub 2010. PMID: 20802181.
- Zhang L, Wang D, Jiang W, Edwards D, Qiu W, Barroihet LM, Rho JH, Jin L, Seethappan V, Vitonis A, Wang J, Mok SC, Crum C, Cramer DW, Ye B. Activated networking of platelet activating factor receptor and FAK/STAT1 induces malignant potential in BRCA1-mutant at-risk ovarian epithelium. Reprod Biol Endocrinol 8(1):74. e-Pub 2010. PMID: 20576130.
- Chan WY, Xia CL, Yew DT, Zhao H, Mok SC. Expression of Dab2, a Tumor Suppressor, in the Human Fetal Hippocampus and Neocortex. Neuroembriology and Aging 5:182-190. e-Pub 2010.
- Mok SC, Bonome T, Vathipadiekal V, Bell A, Johnson ME, Wong KK, Park DC, Hao K, Yip DK, Donninger H, Ozbun L, Samimi G, Brady J, Randonovich M, Pise-Masison CA, Barrett JC, Wong WH, Welch WR, Berkowitz RS, Birrer MJ. A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. Cancer Cell 16(6):521-32, 2009. PMID: 19962670.
- Thompson MS, Mok SC. Immunopathogenesis of ovarian cancer. Minerva Med 100(5):357-70, 2009. PMID: 19910889.
- Tung CS, Mok SC, Tsang YT, Zu Z, Song H, Liu J, Deavers MT, Malpica A, Wolf JK, Lu KH, Gershenson DM, Wong KK. PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas. Mod Pathol 22(9):1243-50, 2009. e-Pub 2009. PMID: 19525924.
- Alper O, Stetler-Stevenson WG, Harris LN, Leitner WW, Ozdemirli M, Hartmann D, Raffeld M, Abu-Asab M, Byers S, Zhuang Z, Oldfield EH, Tong Y, Bergmann-Leitner E, Criss WE, Nagasaki K, Mok SC, Cramer DW, Karaveli FS, Goldbach-Mansky R, Leo P, Stromberg K, Weil RJ. Novel anti-filamin-A antibody detects a secreted variant of filamin-A in plasma from patients with breast carcinoma and high-grade astrocytoma. Cancer Sci 100(9):1748-56, 2009. e-Pub 2009. PMID: 19594548.
- Kwong J, Chan FL, Wong KK, Birrer MJ, Archibald KM, Balkwill FR, Berkowitz RS, Mok SC. Inflammatory cytokine tumor necrosis factor alpha confers precancerous phenotype in an organoid model of normal human ovarian surface epithelial cells. Neoplasia 11(6):529-41, 2009. PMID: 19484142.
- Chung TK, Cheung TH, Huen NY, Wong KW, Lo KW, Yim SF, Siu NS, Wong YM, Tsang PT, Pang MW, Yu MY, To KF, Mok SC, Wang VW, Li C, Cheung AY, Doran G, Birrer MJ, Smith DI, Wong YF. Dysregulated microRNAs and their predicted targets associated with endometrioid endometrial adenocarcinoma in Hong Kong women. Int J Cancer 124(6):1358-65, 2009. PMID: 19065659.
- Nevadunsky NS, Barbieri JS, Kwong J, Merritt MA, Welch WR, Berkowitz RS, Mok SC. RUNX3 protein is overexpressed in human epithelial ovarian cancer. Gynecol Oncol 112(2):325-30, 2009. e-Pub 2008. PMID: 18937968.
- Socha MJ, Said N, Dai Y, Kwong J, Ramalingam P, Trieu V, Desai N, Mok SC, Motamed K. Aberrant promoter methylation of sparc in ovarian cancer. Neoplasia 11(2):126-35, 2009. PMID: 19177197.
- Callahan MJ, Nagymanyoki Z, Bonome T, Johnson ME, Litkouhi B, Sullivan EH, Hirsch MS, Matulonis UA, Liu J, Birrer MJ, Berkowitz RS, Mok SC. Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer. Clin Cancer Res 14(23):7667-73, 2008. PMID: 19047092.
- Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, Mueller P, Lenburg ME, Gray JW, Mok S, Birrer MJ, Lopez-Berestein G, Coleman RL, Bar-Eli M, Sood AK. Dicer, drosha, and outcomes in patients with ovarian cancer. N Engl J Med 359(25):2642-2650, 2008. PMID: 19092150.
- Park DC, Yeo SG, Wilson MR, Yerbury JJ, Kwong J, Welch WR, Choi YK, Birrer MJ, Mok SC, Wong KK. Clusterin interacts with Paclitaxel and confer Paclitaxel resistance in ovarian cancer. Neoplasia 10(9):964-72, 2008. PMID: 18714397.
- Nagymanyoki Z, Callahan MJ, Parast MM, Fulop V, Mok SC, Berkowitz RS. Immune cell profiling in intraplacental and postmolar choriocarcinomas. J Reprod Med 53(8):558-64, 2008. PMID: 18773618.
- Nagymanyoki Z, Growdon WB, Sarno J, Callahan MJ, Parast MM, Fulop V, Mok SC, Horowitz N, Berkowitz RS. Vascularization and expression of angiogenic factors in partial and complete molar pregnancies. J Reprod Med 53(8):589-94, 2008. PMID: 18773623.
- Wang D, Zhao Z, Caperell-Grant A, Yang G, Mok SC, Liu J, Bigsby RM, Xu Y. S1P differentially regulates migration of human ovarian cancer and human ovarian surface epithelial cells. Mol Cancer Ther 7(7):1993-2002, 2008. PMID: 18645009.
- Aponte M, Jiang W, Lakkis M, Li MJ, Edwards D, Albitar L, Vitonis A, Mok SC, Cramer DW, Ye B. Activation of platelet-activating factor receptor and pleiotropic effects on tyrosine phospho-EGFR/Src/FAK/paxillin in ovarian cancer. Cancer Res 68(14):5839-48, 2008. PMID: 18632638.
- Nagymanyoki Z, Butler MO, Callahan MJ, Parast MM, Fulop V, Mok SC, Berkowitz RS. Antigen-specific T cell immune response detected by skewed T cell receptor usage in normal placenta and complete molar pregnancy. J Reprod Med 53(7):528-34, 2008. PMID: 18720929.
- Litkouhi B, Litkouhi B, Fleming E, Welch WR, Berkowitz RS, Birrer MJ, Mok SC. Overexpression of CEACAM6 in borderline and invasive mucinous ovarian neoplasms. Gynecol Oncol 109(2):234-9, 2008. e-Pub 2008. PMID: 18331757.
- Gagnon A, Kim JH, Schorge JO, Ye B, Liu B, Hasselblatt K, Welch WR, Bandera CA, Mok SC. Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients. Clin Cancer Res 14(3):764-71, 2008. PMID: 18245537.
- Stany MP, Bonome T, Wamunyokoli F, Zorn K, Ozbun L, Park DC, Hao K, Boyd J, Sood AK, Gershenson DM, Berkowitz RS, Mok SC, Birrer MJ. Classification of ovarian cancer: a genomic analysis. Adv Exp Med Biol 622:23-33, 2008. PMID: 18546616.
- Nagymanyoki Z, Callahan MJ, Parast MM, Berkowitz RS, Mok SC, Fulop V. Overexpression of laminin receptor 1 on decidual cells in partial and complete mole. Gynecol Oncol 108(1):121-5, 2008. e-Pub 2007. PMID: 17928039.
- Cheung KK, Mok SC, Zhao H, Rezaie P, Chan WY. Inhibition of Dab2 expression with antisense oligodeoxynucleotides in mouse embryo. Neuroembryol Aging:89-99, 2008.
- Cheung KK, Mok SC, Rezaie P, Chan WY. Dynamic expression of Dab2 in the mouse embryonic central nervous system. BMC Dev Biol 8:76, 2008. PMID: 18680569.
- Koon EC, Ma PC, Salgia R, Welch WR, Christensen JG, Berkowitz RS, Mok SC. Effect of a c-Met-specific, ATP-competitive small-molecule inhibitor SU11274 on human ovarian carcinoma cell growth, motility, and invasion. Int J Gynecol Cancer 18(5):976-84. e-Pub 2007. PMID: 18021219.
- Nagymanyoki Z, Callahan MJ, Parast MM, Fulop V, Mok SC, Berkowitz RS. Immune cell profiling in normal pregnancy, partial and complete molar pregnancy. Gynecol Oncol 107(2):292-7. e-Pub 2007. PMID: 17878059.
- Lee S, Garner EI, Welch WR, Berkowitz RS, Mok SC. Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma. Gynecol Oncol 106(2):311-7, 2007. e-Pub 2007. PMID: 17532031.
- Birrer MJ, Johnson ME, Hao K, Wong KK, Park DC, Bell A, Welch WR, Berkowitz RS, Mok SC. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. J Clin Oncol 25(16):2281-7, 2007. PMID: 17538174.
- Litkouhi B, Kwong J, Lo CM, Smedley JG, McClane BA, Aponte M, Gao Z, Sarno JL, Hinners J, Welch WR, Berkowitz RS, Mok SC, Garner EI. Claudin-4 overexpression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-terminal fragment of Clostridium perfringens enterotoxin. Neoplasia 9(4):304-14, 2007. PMID: 17460774.
- Nishimura S, Tsuda H, Ito K, Jobo T, Yaegashi N, Inoue T, Sudo T, Berkowitz RS, Mok SC. Differential expression of ABCF2 protein among different histologic types of epithelial ovarian cancer and in clear cell adenocarcinomas of different organs. Hum Pathol 38(1):134-9, 2007. e-Pub 2006. PMID: 16996567.
- Said NA, Najwer I, Socha MJ, Fulton DJ, Mok SC, Motamed K. SPARC inhibits LPA-mediated mesothelial-ovarian cancer cell crosstalk. Neoplasia 9(1):23-35, 2007. PMID: 17325741.
- Park DC, Yeo SG, Shin EY, Mok SC, Kim DH. Clusterin confers paclitaxel resistance in cervical cancer. Gynecol Oncol 103(3):996-1000, 2006. e-Pub 2006. PMID: 16890274.
- Sunde JS, Donninger H, Wu K, Johnson ME, Pestell RG, Rose GS, Mok SC, Brady J, Bonome T, Birrer MJ. Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-beta signaling in ovarian cancer. Cancer Res 66(17):8404-12, 2006. PMID: 16951150.
- Kim KS, Sengupta S, Berk M, Kwak YG, Escobar PF, Belinson J, Mok SC, Xu Y. Hypoxia enhances lysophosphatidic acid responsiveness in ovarian cancer cells and lysophosphatidic acid induces ovarian tumor metastasis in vivo. Cancer Res 66(16):7983-90, 2006. PMID: 16912173.
- Huang KC, Park DC, Ng SK, Lee JY, Ni X, Ng WC, Bandera CA, Welch WR, Berkowitz RS, Mok SC, Ng SW. Selenium binding protein 1 in ovarian cancer. Int J Cancer 118(10):2433-40, 2006. PMID: 16380993.
- Hashiguchi Y, Tsuda H, Inoue T, Berkowitz RS, Mok SC. PTEN expression in clear cell adenocarcinoma of the ovary. Gynecol Oncol 101(1):71-5, 2006. e-Pub 2005. PMID: 16290000.
- Kwong J, Lee JY, Wong KK, Zhou X, Wong DT, Lo KW, Welch WR, Berkowitz RS, Mok SC. Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer. Neoplasia 8(4):268-78, 2006. PMID: 16756719.
- Ye B, Skates S, Mok SC, Horick NK, Rosenberg HF, Vitonis A, Edwards D, Sluss P, Han WK, Berkowitz RS, Cramer DW. Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin Cancer Res 12(2):432-41, 2006. PMID: 16428483.
- Feinberg BB, Jack RM, Mok SC, Anderson DJ. Low erythrocyte complement receptor type 1 (CR1, CD35) expression in preeclamptic gestations. Am J Reprod Immunol 54(6):352-7, 2005. PMID: 16305660.
- Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, Hellstrom I, Mok SC, Liu J, Bast RC. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 99(2):267-77, 2005. e-Pub 2005. PMID: 16061277.
- Feltmate CM, Lee KR, Johnson M, Schorge JO, Wong KK, Hao K, Welch WR, Bell DA, Berkowitz RS, Mok SC. Whole-genome allelotyping identified distinct loss-of-heterozygosity patterns in mucinous ovarian and appendiceal carcinomas. Clin Cancer Res 11(21):7651-7, 2005. PMID: 16278384.
- Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, Brady J, Gardner GJ, Hao K, Wong WH, Barrett JC, Lu KH, Sood AK, Gershenson DM, Mok SC, Birrer MJ. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 65(22):10602-12, 2005. PMID: 16288054.
- Tsuda H, Ito YM, Ohashi Y, Wong KK, Hashiguchi Y, Welch WR, Berkowitz RS, Birrer MJ, Mok SC. Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analyses. Clin Cancer Res 11(19 Pt 1):6880-8, 2005. PMID: 16203778.
- Wang V, Li C, Lin M, Welch W, Bell D, Wong YF, Berkowitz R, Mok SC, Bandera CA. Ovarian cancer is a heterogeneous disease. Cancer Genet Cytogenet 161(2):170-3, 2005. PMID: 16102589.
- Qin S, Ferdinand AS, Richie JP, O'Leary MP, Mok SC, Liu BC. Chromatofocusing fractionation and two-dimensional difference gel electrophoresis for low abundance serum proteins. Proteomics 5(12):3183-92, 2005. PMID: 16035113.
- Zhou X, Rao NP, Cole SW, Mok SC, Chen Z, Wong DT. Progress in concurrent analysis of loss of heterozygosity and comparative genomic hybridization utilizing high density single nucleotide polymorphism arrays. Cancer Genet Cytogenet 159(1):53-7, 2005. PMID: 15860358.
- Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, Hecht JL. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 65(6):2162-9, 2005. PMID: 15781627.
- Huddleston HG, Wong KK, Welch WR, Berkowitz RS, Mok SC. Clinical applications of microarray technology: creatine kinase B is an up-regulated gene in epithelial ovarian cancer and shows promise as a serum marker. Gynecol Oncol 96(1):77-83, 2005. PMID: 15589584.
- Feltmate CM, Mok SC. Whole-genome allelotyping using laser microdissected tissue. Methods Mol Biol 293:69-77, 2005. PMID: 16028411.
- Tsuda H, Birrer MJ, Ito YM, Ohashi Y, Lin M, Lee C, Wong WH, Rao PH, Lau CC, Berkowitz RS, Wong KK, Mok SC. Identification of DNA copy number changes in microdissected serous ovarian cancer tissue using a cDNA microarray platform. Cancer Genet Cytogenet 155(2):97-107, 2004. PMID: 15571795.
- Zhou X, Mok SC, Chen Z, Li Y, Wong DT. Concurrent analysis of loss of heterozygosity (LOH) and copy number abnormality (CNA) for oral premalignancy progression using the Affymetrix 10K SNP mapping array. Hum Genet 115(4):327-30, 2004. PMID: 15290239.
- Wong YF, Cheung TH, Lo KW, Wang VW, Chan CS, Ng TB, Chung TK, Mok SC. Protein profiling of cervical cancer by protein-biochips: proteomic scoring to discriminate cervical cancer from normal cervix. Cancer Lett 211(2):227-34, 2004. PMID: 15219946.
- Ni X, Zhang W, Huang KC, Wang Y, Ng SK, Mok SC, Berkowitz RS, Ng SW. Characterization of human kallikrein 6/protease M expression in ovarian cancer. Br J Cancer 91(4):725-31, 2004. PMID: 15305183.
- Zhou X, Li C, Mok SC, Chen Z, Wong DT. Whole genome loss of heterozygosity profiling on oral squamous cell carcinoma by high-density single nucleotide polymorphic allele (SNP) array. Cancer Genet Cytogenet 151(1):82-4, 2004. PMID: 15120915.
- Schorge JO, Drake RD, Lee H, Skates SJ, Rajanbabu R, Miller DS, Kim JH, Cramer DW, Berkowitz RS, Mok SC. Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. Clin Cancer Res 10(10):3474-8, 2004. PMID: 15161704.
- Tsuda H, Bandera CA, Birrer MJ, Hashiguchi Y, Berkowitz RS, Mok SC. Cyclin E amplification and overexpression in clear cell adenocarcinoma of the ovary. Oncology 67(3-4):291-9, 2004. PMID: 15557791.
- Zheng Y, Xu Y, Ye B, Lei J, Weinstein MH, O'Leary MP, Richie JP, Mok SC, Liu BC. Prostate carcinoma tissue proteomics for biomarker discovery. Cancer 98(12):2576-82, 2003. PMID: 14669276.
- Kim JH, Herlyn D, Wong KK, Park DC, Schorge JO, Lu KH, Skates SJ, Cramer DW, Berkowitz RS, Mok SC. Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer. Clin Cancer Res 9(13):4782-91, 2003. PMID: 14581349.
- Zorn KK, Jazaeri AA, Awtrey CS, Gardner GJ, Mok SC, Boyd J, Birrer MJ. Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies. Clin Cancer Res 9(13):4811-8, 2003. PMID: 14581352.
- Ye B, Cramer DW, Skates SJ, Gygi SP, Pratomo V, Fu L, Horick NK, Licklider LJ, Schorge JO, Berkowitz RS, Mok SC. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res 9(8):2904-11, 2003. PMID: 12912935.
- Bandera CA, Tsui HW, Mok SC, Tsui FW. Expression of cytokines and receptors in normal, immortalized, and malignant ovarian epithelial cell lines. Anticancer Res 23(4):3151-7, 2003. PMID: 12926048.
- Ho SM, Lau KM, Mok SC, Syed V. Profiling follicle stimulating hormone-induced gene expression changes in normal and malignant human ovarian surface epithelial cells. Oncogene 22(27):4243-56, 2003. PMID: 12833147.
- Batorfi J, Fulop V, Kim JH, Genest DR, Doszpod J, Mod SC, Berkowitz RS. Osteopontin is down-regulated in hydatidiform mole. Gynecol Oncol 89:134-139, 2003.
- Batorfi J, YE B, Mok SC, Cseh I, Berkowitz RS, Fulop V. Protein profiling of complete mole and normal placenta using ProteinChip analysis on laser capture microdissected cells. Gynecol Oncol 88:424-428, 2003.
- Schorge JO, Mok SC. Understanding the pathogenesis of primary peritoneal carcinoma: involvement of the BRCA1 and p53 genes. Hum Pathol 30(2):115-6, 1999. PMID: 10029436.
- Lu KH, Cramer DW, Muto MG, Li EY, Niloff J, Mok SC. A population-based study of BRCA1 and BRCA2 mutations in Jewish women with epithelial ovarian cancer. Obstet Gynecol 93(1):34-7, 1999. PMID: 9916952.
- Iyengar TD, Ng S, Lau CC, Welch WR, Bell DA, Berkowitz RS, Mok SC. Differential expression of NF1 type I and type II isoforms in sporadic borderline and invasive epithelial ovarian tumors. Oncogene 18(1):257-62, 1999. PMID: 9926941.
- Bandera CA, Muto MG, Schorge JO, Berkowitz RS, Rubin SC, Mok SC. BRCA1 gene mutations in women with papillary serous carcinoma of the peritoneum. Obstet Gynecol 92(4 Pt 1):596-600, 1998. PMID: 9764635.
- Bandera CA, Muto MG, Welch WR, Berkowitz RS, Mok SC. Genetic imbalance on chromosome 17 in papillary serous carcinoma of the peritoneum. Oncogene 16(26):3455-9, 1998. PMID: 9692553.
- Fulop V, Colitti CV, Genest D, Berkowitz RS, Yiu GK, Ng SW, Szepesi J, Mok SC. DOC-2/hDab2, a candidate tumor suppressor gene involved in the development of gestational trophoblastic diseases. Oncogene 17(4):419-24, 1998. PMID: 9696034.
- Lu KH, Bell DA, Welch WR, Berkowitz RS, Mok SC. Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors. Cancer Res 58(11):2328-30, 1998. PMID: 9622067.
- Schorge JO, Muto MG, Welch WR, Bandera CA, Rubin SC, Bell DA, Berkowitz RS, Mok SC. Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations. J Natl Cancer Inst 90(11):841-5, 1998. PMID: 9625172.
- Mok SC, Chan WY, Wong KK, Cheung KK, Lau CC, Ng SW, Baldini A, Colitti CV, Rock CO, Berkowitz RS. DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer. Oncogene 16(18):2381-7, 1998. PMID: 9620555.
- Quayle AJ, Porter EM, Nussbaum AA, Wang YM, Brabec C, Yip KP, Mok SC. Gene expression, immunolocalization, and secretion of human defensin-5 in human female reproductive tract. Am J Pathol 152(5):1247-58, 1998. PMID: 9588893.
- Fulop V, Mok SC, Genest DR, Szigetvari I, Cseh I, Berkowitz RS. c-myc, c-erbB-2, c-fms and bcl-2 oncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma. J Reprod Med 43(2):101-10, 1998. PMID: 9513871.
- Fulop V, Mok SC, Genest DR, Gati I, Doszpod J, Berkowitz RS. p53, p21, Rb and mdm2 oncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma. J Reprod Med 43(2):119-27, 1998. PMID: 9513873.
- Edelson MI, Lau CC, Colitti CV, Welch WR, Bell DA, Berkowitz RS, Mok SC. A one centimorgan deletion unit on chromosome Xq12 is commonly lost in borderline and invasive epithelial ovarian tumors. Oncogene 16(2):197-202, 1998. PMID: 9464537.
- Edelson MI, Scherer SW, Tsui LC, Welch WR, Bell DA, Berkowitz RS, Mok SC. Identification of a 1300 kilobase deletion unit on chromosome 7q31.3 in invasive epithelial ovarian carcinomas. Oncogene 14(24):2979-84, 1997. PMID: 9205105.
- Tsao SW, Mok CH, Knapp RC, Oike K, Muto MG, Welch WR, Goodman HM, Sheets EE, Berkowitz RS, Lau CC. Molecular genetic evidence of a unifocal origin for human serous ovarian carcinomas. Gynecol Oncol 48(1):5-10, 1993. PMID: 8423021.
Invited Articles
- Yeung TL, Leung CS, Yip KP, Au Yeung CL, Wong ST, Mok SC. Cellular and molecular processes in ovarian cancer metastasis. Am J Physiol Cell Physiol 309(7):ajpcell.00188.2015, 2015. e-Pub 2015. PMID: 26224579.
- Lu KH, Yates MS, Mok SC. The monkey, the hen, and the mouse: Models to advance ovarian cancer chemoprevention. Cancer Prev Res (Phila) 2(9):773-5, 2009. e-Pub 2009. PMID: 19737981.
- Tung CS, Wong KK, Mok SC. Biomarker discovery in ovarian cancer. Womens Health (Lond Engl) 4:27-40, 2008. PMID: 19072449.
- Ye B, Gagnon A, Mok SC. Recent technical strategies to identify diagnostic biomarkers for ovarian cancer. Expert Rev Proteomics 4(1):121-31, 2007. PMID: 17288520.
- Mok SC, Elias KM, Wong KK, Ho K, Bonome T, Birrer MJ. Biomarker discovery in epithelial ovarian cancer by genomic approaches. Adv Cancer Res 96:1-22, 2007. PMID: 17161674.
- Mok SC, Kwong J, Welch WR, Samimi G, Ozbun L, Bonome T, Birrer MJ, Berkowitz RS, Wong KK. Etiology and pathogenesis of epithelial ovarian cancer. Dis Markers 23(5-6):367-76, 2007. PMID: 18057520.
- Samimi G, Ozbun L, Johnson ME, Mok SC, Birrer MJ. Biomarkers of mucinous tumors of the ovary. Dis Markers 23(5-6):389-96, 2007. PMID: 18057522.
- Fulop V, Mok SC, Berkowitz RS. Molecular biology of gestational trophoblastic neoplasia: a review. J Reprod Med 49(6):415-22, 2004. PMID: 15283047.
- Terry KL, Sluss PM, Skates SJ, Mok SC, Ye B, Vitonis AF, Cramer DW. Blood and urine markers for ovarian cancer: a comprehensive review. Dis Markers 20(2):53-70, 2004. PMID: 15322314.
- Bandera CA, Ye B, Mok SC. New technologies for the identification of markers for early detection of ovarian cancer. Curr Opin Obstet Gynecol 15(1):51-5, 2003. PMID: 12544502.
- Fulop V, Mod SC, Gati I, Berkowitz RS. Recent advances in molecular biology of gestational trophoblastic diseases. J Reprod Med 47:369-379, 2002.
- Auersperg N, Edelson MI, Mok SC, Johnson SW, Hamilton TC. The biology of ovarian cancer. Semin Oncol 25(3):281-304, 1998. PMID: 9633841.
- Wong KK, Mok SC. Molecular genetics of ovarian cancer. Ovarian Cancer.
- Mok SC, Wong KK, Lu K, Nagymanyoki Z. Molecular basis of gynecologic diseases. Molecular Pathology.
Book Chapters
- Feltmate C, Mok SC. Whole genome allelotyping on laser-based microdissected tissue. In: Laser Capture Microdissection: methods and protocols. The Humana Press Inc: Totowa, New Jersey, 69-77, 2004.
- Wong KK, Cheng R, Kim JK, Mok SC. Gene expression analysis of ovarian tumors with a cDNA microarray containing ovarian tumor-specific clones. In: Perspectives In Gene Expression. BioTechniques Press: Natick, Massachusetts, 2003.
- Mok SC, Schorge JO, Welch WR, Hendrickson MR, Kempson RL. Peritoneal Tumours. In: World Health Organization of Tumours, Pathology & Genetics, Tumours of the Breast and Female Genital Organs. IARC Press, 197-202, 2003.
- Wong KK, Cheng RS, Berkowitz RS, Mok SC. Gene expression analysis of ovarian cancer cells by cDNA microarray. In: Microarray and Cancer. Eaton Publishing: Natick, Massachusetts, 127-138, 2002.
- Mok SC, Lu KH, Ng SW, Yiu GK, Welch WR, Bell DA, Berkowitz RS. Molecular pathogenesis of borderline and invasive ovarian tumors. In: Ovarian Cancer 6. Isis Medical Media, 97-103, 2000.
- Mok SC, Lo KW, Tsao SW. Direct PCR cycle-sequencing of mutated allele detected by PCR-SSCP analysis. In: The PCR Technique: DNA Sequencing II. Eaton Publishing: Natick, Massachusetts, 69-73, 1997.
Grant & Contract Support
| Title: | The Genomic, Epigenomic and Psychosocial Characteristics of Long-Term Survivors of Ovarian Cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-Principal Investigator |
| Title: | Ovarian SPORE Development Research Project: IFITM3: The key to modulate survival rates in patients with BRCA-deficient ovarian cancer |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| Title: | The FGR18/FGR14 amplicon: Novel therapeutic biomarkers for ovarian cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-Principal Investigator |
| Title: | Study of biomarkers in ovarian cancer: Modulation by activity & diet intervention |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
Patient Reviews
CV information above last modified January 11, 2024